看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
4 o0 M6 g! _4 K# [5 N5 t5 e; j, B' ?% J5 ^) w4 p2 q
5 n, S: T; k8 s, S; c! o+ qCurrently available feasibility data for possible combination strategies. 2 J z2 Y3 j5 c0 n. e
————————————————————————————————
* E4 D& k7 n% LCombination Feasibility according to preliminary data + o' e% a# t+ l! F! L2 P* d- K
——————————————————————————————————
7 n% V6 H; L; ~/ j; W7 r% ^$ X) EBevacizumab + sorafenib Yes, reduced dose
" U& _6 e9 a) J2 F' y, B# V# G( _! o+ iBevacizumab + sunitinib† No & O% I) B7 H4 y9 Y* T
Bevacizumab + temsirolimus Yes
4 t7 B" K% {- |: X* l7 I! pBevacizumab + everolimus Yes
* S: C o& J) q: Y0 \; `Sorafenib + sunitinib ?
% ~4 T" O0 i' P" ]5 d ySorafenib + temsirolimus Yes, reduced dose . ^. M! ~) c" Q) U' L) b: t/ h1 s
Sorafenib + everolimus Yes, reduced dose
' A; Y! g% z! B+ i, h `Sunitinib + temsirolimus† No : Y/ U- w5 H8 t- [
Sunitinib + everolimus ? 0 G& K2 o) L/ m( E r- B; X
Temsirolimus + everolimus ? 2 m; q+ Q1 i3 J; P% `. @
————————————————————
+ |; A2 }4 S1 l; m( |6 q†Led to US FDA warning.' \8 B. b- X% f0 s$ b
?: As yet unattempted combination.
1 u; _( V7 H/ t+ b5 e# N4 | |